WALTHAM & CAMBRIDGE, Mass.--(BUSINESS WIRE)--X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a key protein complex that orchestrates nutrient-mediated cellular metabolism and growth. The compounds licensed by Navitor were discovered by X-Chem screening their proprietary DEX platform against protein targets supplied by Navitor under a drug discovery agreement established by the parties in 2014. X-Chem received research funding from Navitor upon initiation of the agreement and a license fee upon exercise of the license. X-Chem is also eligible for additional consideration upon achievement of further milestones. Financial details were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
